⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11262365 | 0.72 | — | — | |
| SCHEMBL1006909 | 0.65 | — | — | |
| SCHEMBL720480 | 0.65 | — | — | |
| SCHEMBL7847555 | 0.61 | — | — | |
| SCHEMBL10427707 | 0.61 | — | — | |
| SCHEMBL3188225 | 0.61 | — | — | |
| SCHEMBL667678 | 0.61 | — | — | |
| SCHEMBL10427686 | 0.61 | — | — | |
| SCHEMBL2726510 | 0.61 | — | — | |
| SCHEMBL61233 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970583-B2 | Therapeutic dendrimer | STARPHARMA PTY LTD. (AU) | 2024-04-30 | — | — | US | disclosed |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2022-12-15 | — | — | US | disclosed |
| US-20210403648-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2021-12-30 | — | — | US | disclosed |
| US-20210380765-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2021-12-09 | — | — | US | disclosed |
| EP-3898613-A1 | ANTICANCER COMPOUNDS | Pharma Mar S.A. (ES) | 2021-10-27 | — | — | EP | disclosed |
| US-11118016-B2 | Therapeutic dendrimer | STARPHARMA PTY LTD. (AU) | 2021-09-14 | — | — | US | disclosed |
| EP-3823961-A1 | THERAPEUTIC DENDRIMER | Starpharma Pty Limited (AU) | 2021-05-26 | — | — | EP | disclosed |
| US-20210100910-A1 | MACROMOLECULES | STARPHARMA PTY LTD. (AU) | 2021-04-08 | — | — | US | disclosed |
| WO-2021056077-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD (AU) | 2021-04-01 | — | — | WO | disclosed |
| US-20200392295-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2020-12-17 | — | — | US | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020014750-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD (AU) | 2020-01-23 | — | — | WO | disclosed |
| US-10174132-B2 | Heparan sulfate synthesis | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180326081-A1 | MACROMOLECULES | STARPHARMA PTY LTD. (AU) | 2018-11-15 | — | — | US | disclosed |
| US-20160060365-A1 | HEPARAN SULFATE SYNTHESIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20120142560-A1 | HEPARAN SULFATE SYNTHESIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2414371-A2 | HEPARAN SULFATE SYNTHESIS | The University Of Georgia Research Foundation, Inc (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010117803-A2 | HEPARAN SULFATE SYNTHESIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-0583971-A1 | Piperidine derivatives | SANKYO COMPANY LIMITED (JP) | 1994-02-23 | — | — | EP | disclosed |